文献速递急性肾损伤

含福莫特罗的聚合物纳米颗粒靶向肾脏改善小鼠缺血再灌注诱导的急性肾损伤恢复

Kidney targeting of formoterol containing polymeric nanoparticles improves recovery from ischemia reperfusion-induced acute kidney injury in mice.
PubMed 文献 · Kidney Int · 2022-06-30

研究开发了含福莫特罗的可生物降解聚合物纳米颗粒靶向肾脏,在雄性C57Bl/6小鼠缺血再灌注急性肾损伤模型中每日给药,损伤后6天血清肌酐和肾皮质肾损伤分子-1分别较对照降低78%和73%,肾皮质线粒体数量与蛋白恢复至假手术组水平,肾小管坏死减少69%,且未增加心率或降低血压。

要点

  • 靶向肾脏的含福莫特罗纳米颗粒使缺血再灌注小鼠损伤后6天血清肌酐和肾皮质肾损伤分子-1分别较对照降低78%和73%。
  • 纳米颗粒治疗使缺血损伤减少的肾皮质线粒体数量和蛋白恢复至假手术组水平,肾小管坏死减少69%。
  • 即使给药频率从每日减少至每周两次,纳米颗粒仍改善肾脏恢复,且与单用福莫特罗相比未增加心率或降低血压。

核心结论

  • 靶向肾脏递送含福莫特罗纳米颗粒通过降低剂量、给药频率和心脏副作用,改进了缺血再灌注诱导急性肾损伤的标准福莫特罗治疗。

研究设计与样本

  • 研究在雄性C57Bl/6小鼠缺血再灌注急性肾损伤模型中,每日给予含福莫特罗的可生物降解聚合物纳米颗粒,并与对照组比较损伤后6天的肾脏恢复指标。

主要发现

  • 与对照小鼠相比,纳米颗粒治疗组损伤后6天血清肌酐降低78%,肾皮质肾损伤分子-1降低73%。
  • 纳米颗粒治疗使缺血损伤减少的肾皮质线粒体数量和蛋白恢复至假手术组水平,肾小管坏死减少69%。
  • 给药频率从每日减少至每周两次时,纳米颗粒仍改善肾脏恢复。
  • 与单用不含纳米颗粒的福莫特罗相比,纳米颗粒未增加心率也未降低血压。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The β2 adrenergic receptor agonist, formoterol, is an inducer of mitochondrial biogenesis and restorer of mitochondrial and kidney function in acute and chronic models of kidney injury. Unfortunately, systemic administration of formoterol has the potential for adverse cardiovascular effects, increased heart rate, and decreased blood pressure. To minimize these effects, we developed biodegradable and biocompatible polymeric nanoparticles containing formoterol that target the kidney, thereby decreasing the effective dose, and lessen cardiovascular effects while restoring kidney function after injury. Male C57Bl/6 mice, treated with these nanoparticles daily, had reduced ischemia-reperfusion-induced serum creatinine and kidney cortex kidney injury molecule-1 levels by 78% and 73% respectively, compared to control mice six days after injury. With nanoparticle therapy, kidney cortical mitochondrial number and proteins reduced by ischemic injury, recovered to levels of sham-operated mice. Tubular necrosis was reduced 69% with nanoparticles treatment. Nanoparticles improved kidney recovery even when the dosing frequency was reduced from daily to two days per week. Finally, compared to treatment with formoterol-free drug alone, these nanoparticles did not increase heart rate nor decrease blood pressure. Thus, targeted kidney delivery of formoterol-containing nanoparticles is an improvement in standard formoterol therapy for ischemia-reperfusion-induced acute kidney injuries by decreasing the dose, dosing frequency, and cardiac side effects.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Vallorz EL, Janda J, Mansour HM, et al. Kidney targeting of formoterol containing polymeric nanoparticles improves recovery from ischemia reperfusion-induced acute kidney injury in mice. Kidney Int. 2022. PMID: 35779607. doi:10.1016/j.kint.2022.05.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。